Objective: Surgery is the first choice of treatment for localised non-small-cell lung cancer (NSCLC). When making decisions regarding resection, physicians must balance the potential long-term benefits of surgery with the risk of surgery-related death, particularly among elderly patients with multiple co-morbid conditions. In 2005, a predictive model with a preoperative and a postoperative mode to predict survival of an individual patient after NSCLC surgery was created. This model combines the patient-, tumour-and treatment characteristics and can be used to assist in clinical decision making. Till present, this model has not been validated. The purpose of this study was to validate this model in patients operated on for primary NSCLC. Methods: A total of 126 patients underwent surgery for primary NSCLC between January 2002 and December 2006. Required model variables were collected for all patients and inserted into the model. To evaluate the performance of the two models, we assessed these models in terms of both discrimination (resolution) and calibration (reliability). The discriminative ability was measured using the c-index and calibration was evaluated by the Hosmer-Lemeshow goodness-of-fit test. Results: The median follow-up time was 3.4 years. Hospital mortality was 2.4%. One-, 2-and 3-year survival was 86%, 75% and 72%, respectively. The discriminative ability of the preoperative mode showed a c-statistic for 1-year survival of 0.68, for 2-year of 0.68 and for 3-year of 0.66. The postoperative model showed a discriminative ability for 1-year survival of 0.72, for 2-year of 0.76 and for 3-year of 0.77. Calibration was adequate for the first 2 years. The preoperative mode showed a p-value of 0.62 for 1-year survival and 0.14 for 2-year survival. Calibration was poor for 3-year survival ( p = 0.0027). For the postoperative mode, calibration was quite similar with p-values of 0.4 for 1-year survival, 0.14 for 2-year survival and 0.003 for 3-year survival. Conclusions: The model adequately estimates the 1-and 2-year survival. Discrimination was good for 3-year survival. Inclusion of more factors with additional prognostic value could potentially further improve the accuracy of the model. #
Introduction
Lung cancer is the leading cause of death in many developed countries [1] . Of all cases, approximately 80% are classified as non-small-cell lung cancer (NSCLC). Surgery is still the first choice of treatment for localised NSCLC if the patient's physical condition is no contraindication. Approximately 25% of patients are diagnosed with stage I or II disease for which surgical resection offers possibility of cure. When making decisions regarding resection, physicians must balance the potential long-term benefits of surgery with the risk of surgery-related death, particularly among patients with multiple co-morbid conditions or elderly patients with limited life expectancy. In this regard, in 2005, Birim et al.
created a model with a preoperative and a postoperative mode that predicts survival for patients after NSCLC surgery (http://www.cardiothoracicresearch.nl) (Fig. 1) [2] . This model combines the patient-, tumour-and treatment characteristics and can be used to assist in treatment decision making. Till present, this model has not been validated. Therefore, the purpose of this study was to validate the model in patients operated on for primary NSCLC.
Methods

Patients
The medical records of 126 consecutive patients who underwent curative resection for primary NSCLC at the Department of Cardio-Thoracic Surgery of the Erasmus MC Rotterdam between 1 January 2002 and 31 December 2006 were reviewed. The Ethics Committee of the Erasmus MC Rotterdam has approved the conduction of the study. Individual consent for the study was waived. Patients were followed with regular visits to the outpatient clinic. Civil administration personnel were consulted to assess late mortality. Follow-up was completed in all patients through March 2009. Median follow-up time was 3.4 years (range, 0.1-7.1 years). The overall survival time was defined as the difference between the date of surgery and the date of last follow-up.
Hospital mortality was defined as death occurring within 30 days of surgery or any death later during the same postoperative hospital stay.
For all cases, preoperative diagnostic work-up included a complete medical history, physical examination, plain chest radiography, electrocardiography, routine laboratory tests, lung function tests and computed tomography of the chest and upper abdomen. Additional staging procedures, that is, mediastinoscopy, liver, bone and brain scans and positron emission tomography (PET) scans were selectively performed to aid in treatment planning, according to best clinical practice at the time of presentation.
The histological typing was done according to The World Health Organization Histological Typing of Lung Tumours [3] . All tumours were staged according to the international TNM classification [4] . Staging was based on pathological assessment of the primary tumour and surgical sampling of bronchopulmonary, hilar and mediastinal lymph nodes.
To evaluate the performance of the model, the required variables were entered therein. For the preoperative mode, we entered for each patient: age, gender, chronic obstructed pulmonary disease (COPD) (unknown in 10 patients), congestive heart failure, renal disease, any prior tumour and clinical TNM stage. For the postoperative mode, we entered for each patient: age, gender, COPD, congestive heart failure, renal disease, any prior tumour, pathological TNM stage and type of resection. When variables had missing values, we regarded the condition to be absent.
Statistical analysis
Discrete variables are displayed as proportions, continuous variables as means AE standard deviations, unless specified otherwise. Survival curves were estimated by the Kaplan-Meier method. A priori calculation of sample size was not performed. Since the prediction model was partly To evaluate the performance of the preoperative and postoperative mode of the model, we assessed these models in terms of both discrimination (resolution) and calibration (reliability) [5] . The discriminative ability of the model was measured quantitatively using the c-index (area under the receiver operating characteristic (ROC) curve) [6] . A c-index of 1.0 would indicate perfect discrimination, whereas a cindex of 0.50 indicates total absence of discrimination. A value between these extremes is the quantitative measure of a model's ability to distinguish between survivors and nonsurvivors. Calibration was evaluated by the HosmerLemeshow goodness-of-fit test, which investigates prognosis based upon groups, and graphically by a calibration plot [7] . The dashed smooth curve in a calibration plot reflects the non-parametric relation between observed survival and predicted probability of survival. Perfect calibration is represented by the straight dotted line through the origin. A calibration plot can be characterised by an intercept, which should ideally be 0 and indicates the extent that predictions are systematically too low or too high ('calibration-in-thelarge'), and a calibration slope, which should ideally be 1. Triangles are based on quintiles of patients with similar predicted probabilities (including 95% confidence limits). Spikes at the bottom of a calibration plot represent the distribution of predicted probabilities. Models with HosmerLemeshow p-values above 0.05 were generally considered to be calibrated well.
Descriptive statistical analyses were performed with SPSS version 15.0 (SPSS, Chicago, IL, USA) and R version 2.5.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for calculating c-indices, Hosmer-Lemeshow p-values, and constructing ROC curves and calibration plots.
Results
Of the 126 patients included in this analysis, 87 (69%) were men and 39 (31%) women. The mean age at the time of operation was 63 AE 10 years (range 38-83 years). Preoperative patient characteristics are outlined in Table 1 . The types of procedures performed consisted of a wedge resection in four (3.2%) patients, a lobectomy in 82 (65.1%) patients, a bilobectomy in eight (6.3%) patients and a pneumonectomy in 32 (25.4%) patients. The pneumonectomy was left-sided in 20 (15.9%) patients, and right-sided in 12 (9.5%) patients. Tumours were classified histologically as squamous cell carcinoma (51; 41%), adenocarcinoma (53; 42%), large cell carcinoma (20; 16%) and bronchoalveolar cell carcinoma (2; 2%). Patient operative demographics are listed in Table 2 .
Hospital mortality was 2.4% (3/126). One-, 2-and 3-year overall survival was 86% (95% confidence interval 78-91%), 75% (95% confidence interval 67-82%) and 72% (95% confidence interval 63-79%), respectively.
Model discrimination was good for all 3 years. The discriminative ability of the preoperative mode of the model showed a c-statistic of 0.68 for 1-year survival, 0.68 for 2-year survival and 0.66 for 3-year survival. For the postoperative mode of the model, it showed a discriminative Calibration was adequate for the model in the first 2 years. For the preoperative mode, it showed a p-value of 0.62 for 1-year survival and 0.14 for 2-year survival. The calibration was poor for 3-year survival ( p = 0.0027). For the postoperative mode, calibration was quite similar with p-values of 0.4 for 1-year survival, 0.14 for 2-year survival and 0.003 for 3-year survival (Table 3, Fig. 3 ). The calibration plots in Fig. 3 demonstrate an underestimation of survival.
Discussion
We validated a prognostic model that can be used in the clinical setting to predict survival after surgery for NSCLC. This prognostic model is easy to use and can be used soon after NSCLC diagnosis. The prognostic model consists of independent variables and is divided into a preoperative (clinical) and a postoperative (clinicopathological) mode.
The derivation of a model is only the first step in the development of a clinical prediction tool. Before a predictive model can be used clinically, it must also go through validation. Validation is essential to ensure that the original model is applicable to other patient populations. During the derivation process, it may occur that some of the predictive variables included in the model are unique to the study population, and therefore cannot be generalised to other settings. Thus, the model must be validated in independent populations with a varying spectrum of disease and different demographic characteristics to demonstrate the reproducibility of the model's predictive ability [8] . In this study, we showed that both models were able to predict the 1-and 2-year survival well among patients operated on for NSCLC. The discriminative ability of the model is better in the postoperative mode than in the preoperative mode. The 1-and 2-year survival calibration rates and plots are good, but the 3-year shows a less good fit. The calibration plots indicate that both models underestimate the survival compared with the observed survival, leaving room for further improvement of the model. Future research should be focussed towards updating these models to reflect improved chances of survival. In this regard, some molecular and biomarker advances in lung cancer research will lead to new and promising prognostic factors. Mutations in epidermal growth factor receptor, for example, which have a favourable prognosis, could be one of the candidate prognostic factors [9, 10] . Although these biomarkers have already been identified, these results still have to be confirmed and validated on a larger scale [11, 12] . Several genome-wide expression microarray-based prognostic models of lung cancer have been reported. Such array-based technology may be suboptimal for clinical use due to the need for specialised laboratory facilities and complex statistical analyses [13] [14] [15] [16] [17] . Prognostic models based on gene expression of a limited number of genes using quantitative real-time polymerase chain reaction (RT-PCR) may be more practical from a clinical point of view. RT-PCR, considered the gold standard for the measurement of gene expression, is highly reproducible and is relatively simple to analyse. Two recently reported RT-PCR-based prognostic models of lung cancer allowed a risk stratification in patients with resected NSCLC, although it is unclear whether they predicted outcome better than clinicopathological factors upon which the Birim model is based [18, 19] . In the future, a combination of genetic factors, clinicopathological factors, molecular markers and biomarkers will possibly lead to a model with a higher accuracy.
A limitation of this study is the relatively short follow-up, which means that we cannot accomplish a long-term validation of the model. Another limitation is that the model is based on the old TNM staging system. Although the TNM staging system was revised in 2009 [20] , the previous TNM stages have to be used for the model. This is the first time that the performance of this model was tested in a different population than it was derived from. On the other hand, patient data from the same region as the original model were used, which could bias the results. In clinical practice, the model can be used in different ways. The preoperative mode can be used as a first evaluation to estimate survival of an individual patient and identify patients with poor prognosis. The postoperative mode can either be used preoperatively to estimate survival assuming the type of resection planned and that clinical tumour stage will not alter after resection, or it can be used postoperatively when the type of resection and the pathological tumour stage have been established.
In the present study, we validated a simple prognostic model with a preoperative and a postoperative mode that estimates survival of patients who have undergone surgery for NSCLC. The model adequately estimates the 1-and 2-year survival. Discrimination was also good for 3-year survival. In general, the model underestimates the survival compared with the observed survival. The model could assist clinicians in informing patients in the preoperative and postoperative setting. Inclusion of more factors with additional prognostic value and inclusion of the new TNM classification could potentially further improve the accuracy of the model. Few studies in the past 10 years have sought to address the fundamental question of prognostic survival model after nonsmall-cell lung cancer (NSCLC) surgery. Indeed, very little is known to date about adequately predicting survival with relevant pre-or postoperative parameters. The decision to perform an operative procedure requires careful assessment of the potential risks and benefits involved, particularly in terms of survival. Risk is usually assessed by applying knowledge both from published sources -surgical series in the literature and registry data -and from the personal experience -clinical acuity -of the physicians who will perform the procedure. A number of biases, however, may contribute to the difficulty of predicting the likelihood of an event [1] . It is now well known that quantitative methods that discriminate factors associated with survival and the integration of this information by predictive models of clinical rules [2] are beneficial both to physicians and to their patients.
The current issue of the European Journal of Cardiothoracic Surgery publishes the remarkable work of the Erasmus University team concerning the validation of a prognostic model (with a preoperative and a postoperative mode) to predict survival [3] , on a cohort of patients operated on for primary NSCLC. In the present article, the authors add to their previous contribution [4] by investigating the evaluation of the performance -assessed in terms of both discrimination (resolution) and calibration (reliability)
-of a prognostic model of survival. In a cohort of 126 patients, the results showed that the discriminative ability of the best model -postoperative -varies from 0.72 to 0.77 and that calibration was adequate for the first 2 years but poor for 3-year survival. Finally, they concluded that the model adequately estimates 1-and 2-year survival and that discrimination was good for 3-year survival.
Why should thoracic surgeons be concerned with prognostic models or interested in this rigorous study? Not only have prognostic models of survival after lung cancer surgery seldom been reported, but this stimulating article also raises a very crucial question from the standpoint of medical care and billing in that it identifies a subpopulation of patients who would benefit -or not -from a given operation. In other words, unnecessary surgery may be avoided. This prognostic model of survival could be used prospectively to inform and advise patients regarding postoperative survival and retrospectively to enable fair comparisons of outcomes (postoperative advance care management planning, performance comparisons stratified by risk groups). It would also be useful both for calculating the survival of an individual patient and for contrasting expected and observed mortalities for an institution or an independent clinician. Herein lies the merit and the strength of the current article, which advocates the possibility of multiple comparisons -an increasingly dominant concept in the medical community!
